Slideshow

Biologic DMARD Tapering in RA

Belgian researchers sought to determine which patients are appropriate candidates for tapering biologics. In this article, we summarize their findings.

Belgian researchers sought to determine which patients are appropriate candidates for tapering biologics. In this article, we summarize their findings.

References:

1. Dierckx S, Lauwerys BR, Sokolova T, et al. Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost effective in daily clinical practice: DATA from the Brussels UCL RA Cohort [abstract]. Arthritis Rheumatol. 2018;70(suppl 10).

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2024 MJH Life Sciences

All rights reserved.